Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：21
作者：
Schipilliti, Francesca Matilde [1 ]
Drittone, Denise [1 ]
Mazzuca, Federica [2 ]
La Forgia, Daniele [3 ]
Guven, Deniz Can [4 ]
Rizzo, Alessandro [3 ]
机构：
[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy
[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy
[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy
[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye
来源：
HELIYON | 2024年 / 10卷 / 07期
关键词：
Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;
D O I：
10.1016/j.heliyon.2024.e28385
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
引用
收藏
页数：7
相关论文
共 36 条
[31]   Paul Ehrlich's magic bullet concept: 100 years of progress [J].
Strebhardt, Klaus ;
Ullrich, Axel .
NATURE REVIEWS CANCER, 2008, 8 (06) :473-480
[32]   Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies [J].
Tarantino, Paolo ;
Carmagnani Pestana, Roberto ;
Corti, Chiara ;
Modi, Shanu ;
Bardia, Aditya ;
Tolaney, Sara M. ;
Cortes, Javier ;
Soria, Jean-Charles ;
Curigliano, Giuseppe .
CA-A CANCER JOURNAL FOR CLINICIANS, 2022, 72 (02) :165-182
[33]   Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer [J].
von Minckwitz, G. ;
Huang, C. -S. ;
Mano, M. S. ;
Loibl, S. ;
Mamounas, E. P. ;
Untch, M. ;
Wolmark, N. ;
Rastogi, P. ;
Schneeweiss, A. ;
Redondo, A. ;
Fischer, H. H. ;
Jacot, W. ;
Conlin, A. K. ;
Arce-Salinas, C. ;
Wapnir, I. L. ;
Jackisch, C. ;
DiGiovanna, M. P. ;
Fasching, P. A. ;
Crown, J. P. ;
Wuelfing, P. ;
Shao, Z. ;
Caremoli, E. Rota ;
Wu, H. ;
Lam, L. H. ;
Tesarowski, D. ;
Smitt, M. ;
Douthwaite, H. ;
Singel, S. M. ;
Geyer, C. E., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07) :617-628
[34]   A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments [J].
Xu, Binghe ;
Ma, Fei ;
Wang, Tao ;
Wang, Shusen ;
Tong, Zhongsheng ;
Li, Wei ;
Wu, Xinhong ;
Wang, Xiaojia ;
Sun, Tao ;
Pan, Yueyin ;
Yao, Herui ;
Wang, Xian ;
Luo, Ting ;
Yang, Jin ;
Zeng, Xiaohua ;
Zhao, Weihong ;
Cong, Xiuyu Julie ;
Chen, Jiongjie .
INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (10) :2134-2144
[35]   Targeting Trop-2 in solid tumors: future prospects [J].
Zaman, Saif ;
Jadid, Hassan ;
Denson, Aaron C. ;
Gray, Jhanelle E. .
ONCOTARGETS AND THERAPY, 2019, 12 :1781-1790
[36]   Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis [J].
Zeng, Ping ;
Chen, Min-Bin ;
Zhou, Li-Na ;
Tang, Min ;
Liu, Chao-Ying ;
Lu, Pei-Hua .
SCIENTIFIC REPORTS, 2016, 6
1234